Dr Per Lundin is Co-Founder & Chief Business Officer of Evox Therapeutics Ltd. He has ~15 years’ experience founding, leading and advising biotech companies developing advanced therapies. Prior to co-founding and building out Evox, he founded and led IsletOne Therapeutics, a cell therapy company developing allogeneic cell therapies for autoimmune and inflammatory diseases, and ultimately sold the business in a PE-led trade sale. Dr Lundin serves as non-executive director of AAV gene therapy company Combigene (Nasdaq First North: COMBI) and board director of Juvenile Diabetes Research Foundation UK (JDRF UK). He is a qualified European Patent Attorney with extensive business development and licensing experience; he earned his PhD from the Karolinska Institute, his Master of Science in Biotechnology Engineering from the Royal Institute of Technology, and his Master of Business Administration from Stockholm University School of Business.